Low-dose Radiotherapy in iNHL

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES · Sep 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of low-dose radiotherapy on indolent lymphoma, a type of slow-growing cancer. The researchers want to see how effective and safe a specific treatment plan, which includes giving a total of 12 Gy of radiation in a series of four smaller doses (3 Gy each), is for patients with this condition. The trial is currently recruiting participants aged between 65 and 74 years, and it is open to people of any gender.

To join the study, participants must have a confirmed diagnosis of indolent lymphoma and be able to provide signed consent to take part. Certain individuals, such as those who have previously received radiation treatment in the same area or have specific types of cancer affecting the gastrointestinal tract, may not be eligible. If you participate, you can expect to receive the low-dose radiotherapy and be monitored closely for any side effects and the treatment's effectiveness. This trial is an important step in understanding how to improve treatment options for patients with indolent lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathology proved iNHL
• • ECOG PS ≤3
• • Signed Informed consent
• Exclusion Criteria:
• • History of radiotherapy at the same site
• • Primary malignant lymphoma of the gastrointestinal tract
• • CTV (Clinical Target Volume)\>500ml
• • Others that researchers consider inappropriate